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Department of Pharmacology, Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India
The efficacy of lamotrigine in the treatment of focal epilepsies have already been
reported in several case reports and open studies, which is thought to act by inhibiting
glutamate release through voltage-sensitive sodium channels blockade and neuronal
membrane stabilization. However, recent findings have also illustrated the importance
of lamotrigine in alleviating the depressive symptoms of bipolar disorder, without causing
mood destabilization or precipitating mania. Currently, no mood stabilizers are available
having equal efficacy in the treatment of both mania and depression, two of which forms
the extreme sides of the bipolar disorder. Lamotrigine, a well established anticonvulsant
has received regulatory approval for the treatment and prevention of bipolar depression
in more than 30 countries worldwide. Lamotrigine, acts through several molecular
targets and overcomes the major limitation of other conventional antidepressants by
stabilizing mood from “below baseline” thereby preventing switches to mania or episode
acceleration, thus being effective for bipolar I disorder. Recent studies have also
suggested that these observations could also be extended to patients with bipolar II
disorder. Thus, lamotrigine may supposedly fulfill the unmet requirement for an effective
depression mood stabilizer.
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INTRODUCTION
Management of bipolar disorders has given main focus on the treatment of acute mania, while
neglecting the treatment of bipolar depression, both of which constitutes the extreme poles of the
bipolar disorder (Podawiltz, 2012). However, greater interests in the therapeutic strategies that
address the two extremities of the bipolar illness has resulted from the ever increased recognition
of the importance of bipolar depression (Judd et al., 2002, 2003). Bipolar depression is considered to
be a chronic illness and its episodes cause a great deal of suffering for patients as well as their family
members (Bowden, 2010). Patients with bipolar depression are currently treated with medications
such as mood stabilizers lithium, valproate and carbamazepine, or antidepressants (Yatham et al.,
1997). Bipolar disorder which is also known as maniac-depression can be precisely described as a
medical illness that is treatable and is marked by extreme changes in mood, thoughts, energy and
behavior that can alternate between the poles of mania and depression, which could probably last
for hours, days, weeks, or even months (Grande et al., 2015). Mood swings that accompany patients
with bipolar disorder can be severe which could range from deep despair to extremes in energy
having experience of “highs” and “lows” of the illness, which usually begins in the late adolescence
appearing as depression during teen years. It could also be initiated in the early childhood or
even as late as in the 40 and 50s (Ketter and Calabrese, 2002). Lamotrigine [3,5-diamino-6
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(2,3-dichlorophenyl-1,2,4-triazine)] is an established
anticonvulsant drug. It is approved for the treatment of focal
epilepsies in the presence or absence of secondary generalization
(Cheung et al., 1992).
Over the past few years, lamotrigine has also been found
effective in the treatment of bipolar disorder being more
efficacious in treating the depressive phase of the illness (Bowden
et al., 1999; Reid et al., 2013). For the better understanding of
the actions of currently available treatment options available, a
new nomenclature for the bipolar disorder has been proposed
in which “above baseline” comprises of events of mania,
hypomania, and mixed state while depression and subsyndromal
depression forms “below baseline.” On this basis, mood stabilizers
could be categorized into two classes as Class A (mania
mood stabilizers) and Class B (depression mood stabilizers;
Ketter and Calabrese, 2002; Henry and Etain, 2010). For better
understanding, depression mood stabilizers can be defined as the
agents having the ability of stabilizingmood from “above baseline”
with causing depression, while mania mood stabilizers could be
defined as the agents capable of stabilizing mood from “below
baseline” without switching back to mania (Herman, 2004). This
novel nomenclature helps o serve the purpose of givingmore focus
to areas of unmet need in the management of bipolar disorder.
There is an urgent need of the depression mood stabilizers
for the treatment of bipolar depression as the conventional
antidepressants that are used commonly for the acute treatment
of bipolar depression fails the requirements of the definition of
“depression mood stabilizers” mainly because of their tendency
to cause mood destabilization by inducing switches to mania or
episode acceleration (Post et al., 1997; Henry et al., 2001; Ketter
and Calabrese, 2002; Sienaert et al., 2013). Lamotrigine possess
the unique characteristic that differentiates it from the othermood
stabilizers and anticonvulsants in its efficacy in bipolar disorder,
as it exerts a positive effect on the corticolimbic network function,
which is a resultant of abnormal activities of the circuits in bipolar
depression (Reid et al., 2013). Lamotrigine is currently known for
treating the depressive phase of bipolar I disorder (Bowden et al.,
1999; Large et al., 2009). Although prevention of the relapse of
depression in bipolar I disorder by lamotrigine monotherapy has
been well demonstrated in the long-term studies, date regarding
the same for the treatment of bipolar II disorder is scare (Bowden
et al., 2003; Calabrese et al., 2003a). However, recent studies
have suggested the long-term effectiveness of lamotrigine in
treating patients with treatment-resistant bipolar II depression,
with having obtained higher recovery rates from antidepressant
augmentation with lamotrigine (Nierenberg et al., 2006; Sharma
et al., 2008).
LAMOTRIGINE: A DEPRESSION MOOD
STABILIZER
Lamotrigine, an anticonvulsant drug is one such widely studied
medication whose therapeutic efficacy has been extended even
beyond its use as a mood stabilizer (Bowden and Singh,
2012). Lamotrigine monotherapy is recently used to control the
depressive symptoms as observed in bipolar disorder suggesting
its profound role in the management of bipolar depression (Ketter
et al., 2008; Yatham et al., 2009). Lamotrigine is used primarily
as an anticonvulsant for the treatment of generalized and partial
seizures and is effective for treating focal epilepsies in the presence
or absence of secondary generalization (Cheung et al., 1992; Kwan
and Brodie, 2001; Bazil, 2002; Goldenberg, 2010). Antiepileptic
activity of lamotrigine is mainly attributed to the inhibition of
the voltage-sensitive sodiumchannels of the neuronalmembrame,
inhibition of the release of the excitatory amino acids such as
glutamate and aspartate, and blockade of the calcium-channel
(Cheung et al., 1992; Xie et al., 1995; Cunningham and Jones,
2000). The exact mechanism by which lamotrigine acts as a
mood stabilizer remains unclear. Over several decades, there has
been increased interest in the treatment of bipolar disorder by
using medications such as carbamazepine and oxcarbazepine,
which are the established antiepileptic agents as well as new
generation antiepileptics such as lamotrigine and topiramate
along with certain most widely used antidepressants were known
to exhibit calcium-channel-blocking properties that are relevant
to the pathophysiology of epilepsies. This property is also desired
for alleviating depressive symptoms. Lamotrigine, however stands
distinctive from the other antidepressants for treating bipolar
depression in its cellular and molecular effects and in comparison
with placebo, lamotrigine is considered as superior as it prolongs
the time to intervention for depression (Grunze and Walden,
2002; Calabrese et al., 2003a,b). Even though mood stabilizing
properties are also exhibited by other anticonvulsant drugs,
several trials have shown lamotrigine to be outstandingly effective
in the prevention or amelioration of bipolar depression in patients
experiencing episodes of major depression as lamotrigine possess
very low propensity for inducing switch to mania, which is major
limitation with the use of other conventional antidepressants and
also for preventing episodes of depression in patients diagnosed
with rapid cycling bipolar disorder (Calabrese et al., 1999a,b, 2000,
2001).
BIPOLAR DISORDER IN BIPOLAR
I DISORDER
Efficacy of lamotrigine was evaluated in subjects with bipolar
I depression in a double-blind, parallel-group, multicenter trial
(Calabrese et al., 1999a). In this study, lamotrigine 50 mg/d
(n = 66), lamotrigine 200 mg/d (n = 63), or placebo (n = 66)
were given to the patients showing 17-item HDRS score
18. After 7 weeks of treatment, primary measures were not
significantly different secondary measures, had a significantly
superior response rate on mean  SD observed scores on 17-
item HDRS, CGI-Severity of Illness, and CGI-Improvement in
lamotrigine 200 mg/d group. In the four other studies subjects
diagnosed with bipolar I disorder (Calabrese et al., 1999a;
SCA40910 and SCA309241 Calabrese et al., 2008) were treated
with lamotrigine 200 mg/d or placebo. 17-item HDRS total
scores or the MADRS was not significantly different in treated
or placebo, with the exception of 1 trial (Calabrese et al., 1999a).
However, CGI-Improvement score was significantly greater with
lamotrigine treated group in two studies (Calabrese et al., 1999a;
SCA40910 and SCA309241 Calabrese et al., 2008). Amann et al.
(2011) suggested that sufficient evidence are not available to
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recommend use of lamotrigine in the treatment of rapidly-cycling
bipolar I.
LAMOTRIGINE IN BIPOLAR II DISORDER
Many prior studies have been focused on the efficacy of
lamotrigine monotherapy in preventing the depressive relapse in
bipolar I disorder and rapid-cycling disorder. Bipolar II disorder
is characterized by one or more episodes of major depression
which is often accompanied by atleast one hypomania episode. In
contrast to this, bipolar II depression is associated with either one
or more maniac or depressive episodes (mixed episodes) which
may alternate from depressive episode lasting for several weeks or
months to intense maniac symptoms lasting for about the same
duration. In patients with bipolar II disorder, the clinical data for
the long term use of lamotrigine is very limited (Bowden et al.,
2003). Patients suffering from the depressive phase of the bipolar
disorder were suggested with adjunctive lamotrigine treatment,
the usage of which was considered to be safe and well tolerated.
Lamotrigine therapy showed significant response in comparison
to placebo in severely ill patients in a recent meta-analysis
conducted (Geddes et al., 2009). It was found that antidepressant
augmentation with lamotrigine was reported to show higher rates
of recovery in treatment-resistant bipolar I or II disorder. Results
that were obtained from related studies conducted earlier gave
sufficient evidence for the long-term effectiveness of lamotrigine
adjunctive therapy in the management of treatment-resistant
bipolar II depression (Sharma et al., 2008). In comparison with
bipolar I disorder, higher suicidal tendency and psychosocial
impairment was observed in bipolar II disorder. The longitudinal
course of bipolar II disorder is dominated by recurrent depressive
episodes and residual symptoms of depression, which has a
potential to exert strong influence on the psychosocial functioning
levels. Owing to this, the clinical output of bipolar II disorder
can be improved by the proper long-term management of the
depressive symptoms (Endicott et al., 2008; Vieta and Suppes,
2008). With this respect, a naturalistic 52-week follow-up study
was conducted for evaluating the long-term effectiveness of
lamotrigine adjunctive therapy for bipolar II depression, in the
absence of treatment-related mania or hypomania. The results of
which showed that the severity of depression was significantly
reduced throughout 52-weeks in bipolar II disorder. During the
initial 12-week treatment, the rate of response was found to be
64.5% of the adjunctive lamotrigine, when tested in the same
population. Depression was improved during the initial treatment
phase and maintained for about 1 year (Chang et al., 2010).
Management of acute phase of bipolar depression was found
to be ineffective by lamotrigine monotherapy as per the results
obtained from the five randomized trials whereas, addition of
lamotrigine to lithium in treating patients with acute bipolar
depression was found to effective on the basis of the results of a
recently conducted randomized trial (Calabrese et al., 2008; van
der Loos et al., 2009). Augmentation of atypical antipsychotics or
mood stabilizers with lamotrigine is expected to produce additive
or synergistic effects through modulation of sodium channel or
serotonergic regulation (Bourin et al., 2009). The results obtained
from an animal study using sodium channel opener, lamotrigine
showed antidepressant effects due to two different mechanisms
such as inactivation of sodium channels and monoaminergic
neurotransmission suggesting different mode of antidepressant
activity (Prica et al., 2008). Adjunctive use of lamotrigine may be
more beneficial in terms of safety and tolerance as compared to
lamotrigine monotherapy, since patients already receiving mood
stabilizers could easily avail a slower titration of lamotrigine (Joe
et al., 2009).
LAMOTRIGINE IN BIPOLAR DEPRESSION
AUGMENTATION
In various clinical trials lamotrigine use as an augmentation
agent was explored for bipolar disorder with depressive episodes
not responsive to typical mood stabilizers. In a randomized,
double-blind, 7-week pilot trial, lamotrigine augmentation was
compared with citalopram augmentation for bipolar I and
II depression (Schaffer et al., 2006). Total MADRS score
difference was significant for both lamotrigine and citalopram.
Nierenberg et al. (2006) compared lamotrigine, risperidone, and
inositol in a 16-week, randomized, equipoise-stratified study in
subjects with bipolar I or II disorder. Although no significant
difference was found between groups for primary outcome,
subjects in lamotrigine group remained in the randomized
phase significantly longer compared to other groups. van
der Loos et al. (2009) in an 8-week, multicenter, double-
blind, randomized, placebo-controlled trial studied lamotrigine
augmentation to lithium in non-lithium responding subjects,
for treating bipolar depression. This study evaluated efficacy
of lithium plus lamotrigine for the treatment of acute bipolar
depression. MADRS score change was significantly different
between groups. Further, subjects were more responsive in
lithium plus lamotrigine treated group compared to placebo.
In a recent study, Kagawa et al. (2014) reported that in
treatment-resistant depressive plasma lamotrigine concentration
of 12.7mmol/Lmay be a threshold for better therapeutic response.
EFFECT OF LAMOTRIGINE ON 5-HT
RECEPTOR
The antidepressant drug lamotrigine is found to be therapeutically
more effective in the treatment of depressive phase of the
bipolar disorder than in treating hypomania or mania (Bourin
et al., 2005). The use of lamotrigine as an augmentation
drug was suggested from the evidence of the efficacy of the
drug in the treatment of major depressive disorders, which
also includes refractory unipolar depression (Frye et al., 2000;
Barbee and Jamhour, 2002; Rocha and Hara, 2003). The
onset of antidepressant action accelerated when administered in
combination with other classical antidepressants (Normann et al.,
2002). Pilot studies have reported the augmentation therapy of
lamotrigine with SSRI’s (fluoxetine and paroxetine) to be well
tolerated and far more superior in efficacy than that of SSRI
monotherapy (Normann et al., 2002; Barbosa et al., 2003).
In a study, various in vivo evaluations in various regions of
the brain were conducted to understand the effect of lamotrigine
on serotonin (5-hydroxytryptamine, 5-HT)1A-receptor-mediated
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adenyl cyclase responses in various brain areas in the mice. The
results, which were obtained thereafter, suggested a new pathway
which reflected the therapeutic efficacy of various classes of
mood stabilizers. This in vivo study was therefore successful in
explaining lamotrigine’s mode of action that was eventually a
result of downregulation of cortical 5-HT1A-receptor-mediated
adenyl cyclase responses. Thus showing significant role of 5-HT
in the physiopathology of maniac depressive disorder (Vinod and
Subhash, 2002). For quantifying 5-HT1A, 5-HT1B, and 5-HT2A m-
RNA levels in the hippocampus and dorsal prefrontal cortex, the
technique of in situ hybridization was used, as a part of a recent
study of subjects with a history of bipolar disorder. The result of
the same indicated that these subjects showed highly altered 5-
HT receptor m-RNA expression giving more evidence to support
the involvement of 5-HT receptors in the mechanism of action of
lamotrigine in bipolar disorders (Lopez-Figueroa et al., 2004).
Shim et al. (2013) performed electrophysiological studies in
the rat brain to evaluate modulation of the antidepressant-
like effects of sustained administration of carisbamate and
lamotrigine on monoaminergic mystems. They concluded that 5-
HT firing in the DRN is decreased but 5-HT transmission in the
forebrain is enhanced by sustained carisbamate and lamotrigine
administration.
One of the biggest challenges faced in the studies and evaluation
ofmood stabilizers was the development of a valid and satisfactory
animal model for bipolar disorder as it comprised of complex
interplay of episodes of mania, depression, euthymia and mixed
states. The animal models that have been proposed was found
only to be partially matching the bipolar illness and in such
case modeling of either depression or maniac behavior could
be achieved, but not both (Machado-Vieira et al., 2004). The
FST, as compared to all the other models was found to be a
simpler model (Porsolt et al., 1977) and match most of the
required criteria of the illness and it has been used extensively
in the investigations of mechanisms of antidepressant actions
(Redrobe and Bourin, 1999a). FST is also one such sensitive
model to the compounds acting on the 5-HT system (Redrobe
et al., 1996; Redrobe and Bourin, 1997), which was of great
help in the association studies that involved lamotrigine along
with the most specific brain-penetrating ligands for 5-HT1A
and 5-HT1B receptors currently available to study the possible
interaction between the two and also to investigate the potential
antidepressant-like action of lamotrigine (Redrobe and Bourin,
1999b, Tatarczynska et al., 2004). 5-HT1 receptor subtype are
known to exist as “autoreceptors” at the presynaptic level
controlling the release of 5-HT and also exist as “heteroreceptors”
at the postsynaptic level, coupled to adenylate cyclase in
controlling the release of other neurotransmitters (Sarhan and
Fillion, 1998). The subsequent studies showed that only a high
affinity postsynaptic 5-HT1A receptor agonists, a presynaptic
and postsynaptic 5-HT1A/1B receptor antagonists and to a lesser
extend postsynaptic 5-HT1A/1B agonists were able to enhance
the antidepressant-like effect of lamotrigine in FST. All the
data obtained from the study showed significant decrease in
the immobility time of lamotrigine when used in combination
with the various 5-HT ligands indicating the involvement of
postsynaptic 5-HT receptors in activity of lamotrigine. The
antidepressant-like effect of lamotrigine was also known to be
produced by the neurotransmitters regulated by postsynaptic 5-
HT receptors (Bourin et al., 2005). Another study on the effect
of 5HT transmission on lamotrigine reported carbamazepine
and lamotrigine to be the only anticonvulsant drugs to result in
elevated extracellular 5-HT concentrations by inhibiting both in
vitro and in vivo 5-HT uptake (Clifford et al., 1998). Cortical
5-HT1A receptors mediated downregulation of responses also
suggests another possible mechanism of action of lamotrigine
(Vinod and Subhash, 2002).
EFFECT OF LAMOTRIGINE ON THE
NORADRENERGIC RECEPTORS
Evaluation of the antidepressant-like effect of lamotrigine in
the mouse forced swimming test along with the involvement of
noradrenergic system was done in a recent study, the results of
which showed convincing evidence in the reduction of immobility
time in the forced swimming test, the effect of which is mediated
by an interaction with the noradrenergic system, probably with
postsynaptic a1- and a2-adrenoreceptors (Petit-Demouliere et al.,
2005; Consoni et al., 2006). For studying the involvement of
noradrenergic system in antidepressant-like effect of lamotrigine,
a selective inhibitor of the enzyme tyrosine hydroxylase, a-
methyl-p-tyrosine was used which is a rate-limiting enzyme in
the noradrenaline and dopamine synthesis. It was found that
when higher dose this inhibitor was given in combination with
lamotrigine, it produced sedative effect, which was considered to
be responsible for the reversal of the antidepressant-like effect of
lamotrigine. Such reversal of the anti-immobility effect was also
found at lower doses ofa-methyl-p-tyrosine (Kaster et al., 2007). It
was also demonstrated that in mice, a-methyl-p-tyrosine without
affecting the levels of serotonin, reduced levels of dopamine and
noradrenaline (57 and 53% respectively; Mayorga et al., 2001).
Moreover, a temporary reversal in the antidepressant response
to desipramine, mazindol, and mirtazapine was produced by the
acute administration of a-methyl-p-tyrosine (Delgado et al., 1993;
Miller et al., 1996). Lamotrigine was also reported to inhibit the
synaptosomal uptake of serotonin, noradrenaline, and dopamine
in the rat brain which could be an indication that lamotrigine
indirectly affects the noradrenergic system, by the release of
noradrenaline, which could further result in interaction with the
receptors (Southam et al., 1998).
The behavioral models of depression depicting antidepressant-
like responses of certain drugs are seemed to be influenced
by a1- and a2-adrenoreceptors (Kitada et al., 1983; Danysz
et al., 1986; Masuda et al., 2001). When mice were pretreated
with prazosin and yohimbine, it reversed the decrease in the
immobility time evoked by lamotrigine suggesting the underlying
actions of these receptor subtypes in the forced swimming test.
In another study, yohimbine could reverse the antidepressant-
like effect produced by clonidine in the forced swimming test
of mice whereas, there was prevention in the antidepressant-
like action of desipramine when mice were pretreated with
prazosin (O’Neill et al., 2001). Furthermore, when mice were
pretreated with either phenylephrine or clonidine and given in
combination with subeffective doses of lamotrigine, in the mice
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forced swimming test, it produced synergistic antidepressant-like
effects suggesting the involvement of a1- and a2-adrenoreceptors
activation in the mechanism of action of lamotrigine (Kitada
et al., 1983). The immobility time in the forced swimming
test in rats and mice was also found to be decreased by
clonidine, an a2-adrenoreceptor agonist (Cervo and Samanin,
1991; O’Neill et al., 2001). A strong reduction in the locomotor
activity which was produced by the administration of adrenergic
drugs phenylephrine and clonidine was already reported in the
earlier study. However, the more recent study conducted on the
involvement of noradrenergic system in the antidepressant-like
action of lamotrigine reported that inspite of these adrenergic
drugs showing sedative effects (Sukul et al., 1988; Cervo and
Samanin, 1991; Hascoet et al., 1991), they potentiated the
antidepressant-like effect of lamotrigine. The results of this study
also suggested the activation of the postsynaptic a1- and a2-
adrenoreceptors is due to the enhancement of noradrenaline levels
by lamotrigine (Kaster et al., 2007).
EFFICACY OF LAMOTRIGINE:
DYSFUNCTION OF NEURAL NETWORK
IN BIPOLAR DEPRESSION
A better understanding of the mechanisms of action of mood-
stabilizing agents forms a basis of the mechanisms underlying the
pathology of bipolar disorder. For the better understanding of the
efficacy of lamotrigine, assessment of neural activity in different
areas of the brain was undertaken in healthy human volunteers to
study the effects of the drug by activating specific neural circuits
using transcranial magnetic stimulation (TMS) which was used in
combination with functional magnetic resonance imaging (fMRI)
for monitoring the response. This is a significant non-invasive
method for the assessment of motor cortex excitability which also
helps in the stimulation of the cerebral cortex. This method is
also found to be useful in the pharmacological examination of
neuroactive drugs on specific brain circuits (Li et al., 2004; Large
et al., 2009). It was observed from the previous studies which
used TMS (Manganotti et al., 1999; Tergau et al., 2003), it was
expected that lamotrigine 325 mg activated the abductor digiti
minimi muscle by increasing the stimulus following motor cortex
stimulation. TMS-induced motor cortical circuits activation was
observed beneath the stimulator coil in the presence of the drug.
Lamotrigine was also found to show facilitatory effect on the
blood-oxygen-level-dependant (BOLD) response to TMS of the
prefrontal cortex. Application of TMS to the motor cortex showed
that with the reduction in the excitability of the motor cortex,
reduction of the BOLD response was consistent, which was in
line with the sodium channel blocker effects (Paulus et al., 2008).
TMS was applied to the prefrontal cortex in the second part of the
study that elicited BOLD response in the corticolimbic brain areas
such as hippocampus and orbital frontal gyrus thereby showing
increased excitability of prefrontal cortex.
The detailed investigations in the study showed that
anticonvulsant activity of the antiepileptic drugs such as
lamotrigine and valproic acid is conferred to the inhibition of
the brain activation caused by the reduced excitability of the
motor cortex induced by TMS stimulation. However, lamotrigine
exerts a different action in the prefrontal corticolimbic system
on TMS stimulation which shows that lamotrigine differs from
valproic acid in molecular mechanisms of action as increased
TMS-induced BOLD response was observed in corticolimbic
circuits when TMS was applied over the dorsolateral prefrontal
cortex (Li et al., 2006). This contrasting neurological effects of
lamotrigine on the excitability of prefrontal and motor circuits
shows some relevance to the drug’s efficacy in the treatment of
bipolar disorder and epilepsy respectively (Li et al., 2004). Thus,
lamotrigine, anticonvulsant drug, was found to exert a positive
effect on the activity of the corticolimbic circuits in patients with
bipolar disorder.
Further studies for highlighting the facilitatory effects of
lamotrigine on the activity of the corticolimbic system was done
to investigate the in vitro activity of the hippocampus in response
to the drug (Large et al., 2009). It was very much necessary to
study the effects of the drug on the brain neural network, rather
than on the individual neurons (Xie et al., 1995). For this purpose,
the CA3 region of the hippocampus was chosen for studying the
effects of lamotrigine on oscillatory field potentials, manifested at
low concentrations of kainic acid resulted in network oscillations
(Fisahn, 2005), which was believed to be able of mimicking
the physiological neural network activity, responsible for the
encoding and retrieval of memory in the hippocampus (Mann
and Paulsen, 2005). In the hippocampus, it was observed that
the power of the gamma oscillations induced by kainic acid
was enhanced significantly by lamotrigine at concentrations
consistent with the therapeutic range (3–10 mM), in contrast to
valproic acid which had no effect at its therapeutic concentration
of 100 mM. Decreased neural activity was seen with higher
concentrations of lamotrigine (100 mM). The results obtained
from the neuronal network studies provided sufficient evidence of
the facilitatory effects of lamotrigine in healthy volunteers and in
patients with bipolar disorder (Large et al., 2009). Thus, alongwith
the activity of the corticolimbic circuits lamotrigine also exerts a
positive effect on the neural network activity.
Based on this, a hypothesis was drawn that neuroplasticity
dysfunction and cellular resilience formed an important
component of the bipolar disorder. With use of clinically
effective mood stabilizers such as lithium and valproic acid
this approach was utilized (Bachmann et al., 2005; Schloesser
et al., 2008). Efficacy of this approach has suggested a various
intracellular signaling elements like glycogen synthase kinase 3
ß(GSK3 ß), extracellular-signal-regulated kinase (ERK)/mitogen-
activated protein kinase (MAPK) or protein kinase C as the
main targets. However, it was found that lamotrigine differs
markedly from valproic acid and lithium in treating bipolar
disorder as none of the targets for bipolar disorder seemed to
be modulated by lamotrigine, showing greater efficacy for the
prevention/amelioration of episodes of depression rather than
mania (Large et al., 2009).
There are several cellular and molecular actions of lamotrigine
that may contribute to its action in bipolar disorder (Xie and
Hagan, 1998). The main mechanism by which lamotrigine
emerged as a well-established anticonvulsant is due to the
inhibition of neuronal hyperexcitability and modification of
synaptic plasticity via voltage-dependant inhibition of neuronal
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voltage-activated Sodium channels and possible high voltage-
activated Calcium channels, as a result of which excessive
neurotransmitter release in the brain is reduced (Xie et al., 1995).
However, the reason for this mechanism of lamotrigine to exert
its efficacy against depressive phase of the bipolar disorder is quite
unclear.
LAMOTRIGINE IN BIPOLAR DISORDER:
INTERACTIONS WITH THE MOLECULAR
TARGETS
As discussed earlier, some important molecular targets such as
serine/threonine kinase, GSK3 which forms a central component
of theWnt signaling pathway as well as in the other pathways such
as phosphoinositide 3-kinase (PI3K)/Akt intracellular signaling
pathways are known for its important role played in the
regulation of multiple cellular processes such as apoptosis,
metabolism, proliferation, differentiation, synaptogenesis, and
resilience/cellular plasticity (Large et al., 2009). In 1996, GSK3
pathway was first linked to bipolar disorder from the finding
that lithium is a direct inhibitor of GSK3 and it directly as well
as indirectly inhibited GSK3 by increasing the phosphorylation
of Akt, which inturn is responsible for the phosphorylation of
Ser9 (Phiel and Klein, 2001; De Sarno et al., 2002). However,
lamotrigine indirectly acts by attenuation of staurosporine and
heat-shock-induced caspase 3 activity in a cell line responsible
for over expression of GSK3 (Bijur et al., 2000). One interesting
fact from a study was that when cerebral cortical cells or
neuroblastoma was exposed to lamotrigine, glycogen synthase
kinase-3b was inhibited which inturn increased the activity of an
oxidizing enzyme, glutathione S-transferase (Hayes and Strange,
2000; Strange et al., 2001; Bakare et al., 2009). Lamotrigine is
reported to show no significant effects on PKC activity, which in
contrast to valproic acid and lithium are reported to indirectly
result in reduction of the levels and activity of PKC isoforms a
and + in the prefrontal cortex and hippocampus of the rat, which
is not a direct effect on PKC (Lenox et al., 1992; Watson and
Lenox, 1996). Comparative analysis of the effects of four main
mood stabilizers including valproic acid, lithium, carbamazepine
and lamotrigine has proved that there was no activation of the
ERK/MAPK signaling pathway by lamotrigine (Di Daniel et al.,
2005) whereas lithium and valproic acid was found to cause
activation of ERK/MAPKpathway in the cell lines and rat primary
cortical neurons also in the hippocampus and prefrontal cortex of
the rat (Yuan et al., 2001; Einat et al., 2003).
Bipolar disorder is characterized by hyperglutamatergic
neurotransmission and by upregulated arachidonic acid
cascade, which forms a new profound therapeutic target in
the treatment of the disorder (Michael et al., 2003; Zarate
et al., 2003; Clinton and Meador-Woodruff, 2004; Cherlyn
et al., 2010). The mechanism of NMDA receptor-mediated
arachidonic acid signaling which is responsible for triggering a
bipolar disorder is through glutamatergic neurotransmission,
which involves N-methyl-D-aspartate receptors (NMDAR’s).
These receptors allow the extracellular flow of calcium into the
cell, which causes the membrane phospholipid to selectively
release arachidonic acid, via the activation of cPLA2 type IV
(calcium-dependant cytosolic phospholipase A2-IV; Epolia et al.,
2012). Studies show that in bipolar disorder, associated with the
above mechanisms, lamotrigine was found to cause interference
with the glutamatergic neurotransmission that involved the
NMDA receptors. Lamotrigine reduces the presynaptic neuronal
depolarization by acting on the voltage-gated sodium and calcium
channels thereby reducing the release at the excitatory synapse
(Xie and Hagan, 1998; Cunningham and Jones, 2000; Sitges et al.,
2007a,b) as well as through blockade of serotonergic receptors
(Ketter et al., 2003). However, lamotrigine does not produce any
effect on the resting membrane potential, excitatory neuronal
transmission of low-frequency or neuronal excitability (Xie and
Hagan, 1998), even the release of glutamate in the hippocampal
region of the freely moving rats (Ahmad et al., 2004), under basal
conditions. Thus lamotrigine, like many other approved mood-
stabilizers causes inhibition of the arachidonic acid signaling
mediated by the NMDA receptors thereby bringing about down-
regulation of brain metabolic arachidonic acid cascade in the rat
brain, initiated by NMDA (Rapoport and Bosetti, 2002; Rapoport
et al., 2009). Moreover, the post mortem BD rat brain showed
consistent glutamatergic state with up-regulated arachidonic
acid cascade and NMDA receptor signaling markers which
includes COX-2 (cyclooxygenase), PLA2, and PG E synthase
(prostaglandin E synthase) responsible for the conversion of
arachidonic acid to pro-inflammatory Prostaglandin E2, greater
expression of vesicular glutamate transporter I, as well as elevated
levels of protein and m RNA in the rat frontal cortex (Hashimoto
et al., 2007; Rao et al., 2007, 2010; Kim et al., 2011). It was also
found that with chronic lamotrigine treatmentwhen administered
at therapeutically relevant doses, COX-2 protein and m-RNA
was found to be decreased in the rat brain, reduced DNA binding
activity of NF-kB and decreased PG-E2 and thromboxane
(TXB2) concentrations (Lee et al., 2008). Lamotrigine was also
found to suppress ketamine induced perceptual abnormalities
in healthy human volunteers (Anand et al., 2000). Besides its
efficacy in treating bipolar disorder by inhibition of the metabolic
arachidonic cascade, lamotrigine has also been reported for its
neuroprotective effects with respect to bipolar disorder arising
out from its potential to increase the levels of mRNA and
proteins of brain-derived neurotropic factor (BDNF) as well as
by increasing the levels of anti-apoptotic factor B-cell lymphoma
2 (Bcl-2; Chang et al., 2009; Li et al., 2010). Lamotrigine was also
used successfully in the experimental models of cerebral ischemia
as well as in excitotoxicity induced by glutamate (Bacher and
Zornow, 1997; Maj et al., 1998). In the rat brain, down regulation
of BDNF induced by stress was also reversed by LTG (Frye et al.,
2007).
LIMITATIONS OF LAMOTRIGINE
After vigabatrin and felbamate, the third ever new generation
antiepileptic to be commercialized was lamotrigine. However, out
of these two drugs only lamotrigine for studied for its utility as
a mood stabilizer, while the other two were not studied as after
its commercialization as antiepileptics they showed idiosyncratic
side-effects namely aplastic anemia and visual field problems
which has limited their use for treating very special epilepsy cases.
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Undoubtedly, lamotrigine has given the best results as compared
to all other third-generation anticonvulsants in the treatment of
bipolar disorder being more therapeutically effective in treating
the depressive episodes encountered in a bipolar disorder (Vieta,
2004). Despite of its proven importance in bipolar disorder,
several limitations are also exhibited by lamotrigine as reported
by some studies. The data obtained from a controlled clinical
trial using placebo showed positive results for lamotrigine only
in patients with bipolar II disorder. A double-blind placebo-
controlled clinical trial was conducted confirmed that the doses
ranging from 50 to 200 mg/day was found to be very effective
in bipolar depression, however the efficacy as shown by the
Hamilton depression scale was not significant. Lamotrigine was
also reported to show negative results in acute mania as per
the results obtained from two double-blinded placebo-controlled
studies (Vieta, 2004).
Treatment of bipolar II depression with adjunctive lamotrigine
may also be associated with a history of suicide-attempts and
a number of depression-related prior hospitalization in case of
poor response to the adjunctive lamotrigine therapy, as per the
data from the 52-week follow-up study. In case of a history of
previous hospitalization, an increased risk of re hospitalization,
treatment resistance, and depressive relapse was reported (Souery
et al., 2007; Lin et al., 2008). The risk of bipolar disorder
may be well influenced by harm avoidance linked to genetic
variations, which can also alter responses to the pharmacological
treatment (Mandelli et al., 2009). The 52-week naturalistic study
also reported cases of lamotrigine discontinuation among 8.3% of
the study subjects owing to the treatment related adverse events
(Chang et al., 2010). Inspite of its good tolerability profiles with
lower incidences of weight gain, there is a fear of risk of Syndrome
of Steven-Johnson, though very infrequent. Doses of lamotrigine
ranging from 150 to 225 mg/day (Fatemi et al., 1997), which
could also be raised up to 500 mg/day (Dichter and Brodie,
1996) can produce benign rash, reported to appear in 10% of
the cases. However, at the time of initiation of the treatment,
slow titration of the lamotrigine dose could decrease the inherent
risk and incidence of rashes. In patients with bipolar disorder,
lamotrigine however does not show any detrimental impact on
the neurocognitive functions, thereby ensuring the safe and long-
term use of lamotrigine in bipolar disorder (Daban et al., 2006).
Further, in a recent review Parker and McCraw (2015) explored
disconnect between the clinical efficacy and quantified efficacy in
controlled trials. They conclude that iterative process should be
encouraged between efficacy studies and clinical observation.
MODEL FOR MANAGEMENT OF BIPOLAR
DEPRESSION USING LAMOTRIGINE
Various studies regularly reported partial rather than full
response for lamotrigine in bipolar depression, both acute and
maintenance. For depressive symptoms lamotrigine can serve as
first choice drug for augmentation to a primary mood stabilizer
for depressive symptoms. Since lamotrigine has certain limitations
it can be supported with a second drug or non-drug intervention
(Bowden and Singh, 2012). Further a recent study showed that
lower lamotrigine serum concentrations resulted in therapeutic
benefit in-patient with bipolar disorder (Unholzer and Haen,
2015).
CONCLUSION
This review highlights the importance of understanding
the different mechanisms and pathways contributing to the
therapeutic use of the well-established antiepileptic drug
lamotrigine in the management of bipolar disorder, being more
effective in treating the depressive phase of the disorder as well
as how it differs from other clinically relevant mood stabilizers,
conventional antidepressants and anticonvulsants in exerting
its efficacy over bipolar depression. A large double-blind study
showed that lamotrigine monotherapy was far more superior
over placebo in the patients presented with mild to very severe
bipolar depression. It was also demonstrated that lamotrigine
was used either as sole therapy or in adjunct with lithium or
valproic acid in the treatment of bipolar depression, which
is usually well tolerated. Data provided in this review also
focus on the effectiveness of lamotrigine in alleviating bipolar
depression without resulting in mood destabilization and in
showing significant improvements in both depressive as well as
maniac phases of the bipolar disorder. Prefrontal cortex of the
brain which plays an important role in processing emotions as
well as in reward processing has been shown to be disrupted in
bipolar disorder, which was found to be overcome by lamotrigine
by increasing BOLD-response in the hippocampus contrasting
the effects of lamotrigine produced on the motor circuits which
could provide future highlights in the improved therapeutic
targets for bipolar disorder. The value of investigating the effects
of psychoactive drugs on the neural circuits was also reviewed
thereby providing better understanding of lamotrigine’s efficacy
in treating bipolar depression. Lamotrigine is also shown to
possess some limitation, encountered during the course of
the treatment though infrequent. Thus, in comparison with
the mood stabilizers which currently lack the ability to cause
stabilization from “below baseline” lamotrigine is considered to
be given a welcome addition to the treatment options available
in the management of bipolar disorder and the emerging
results from the previous studies also extends its usefulness in
patients with bipolar II disorder and in rapid-cycling disorder,
however more placebo-controlled trials would be required
for the complete confirmation of the efficacy of lamotrigine,
an antiepileptic mood stabilizer in the treatment of bipolar
depression.
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